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ABSTRACT
Homeobox (HOX) family genes encode key transcription factors for embryogenesis 
and may be correlated with carcinogenesis. The aim of this study was to elucidate 
whether aberrant expression of HOX genes influences outcomes in epithelial ovarian 
cancer (EOC). Gene expression data and clinicopathologic information from 630 
patients with EOC were downloaded from The Cancer Genome Atlas database. We 
explored correlations between expression levels of HOX gene family members and 
clinicopathological variables. Higher expression of HOXA1, A4, A5, A7, A10, A11, 
B13, C13, D1, and D3 was associated with advanced FIGO stage. Suboptimal residual 
disease after debulking surgery was significantly correlated with higher expression 
of HOXB9, B13, and C13. Additionally, patients with high expression of HOXC6 and 
C11 were significantly more likely to have poor performance status. Overall survival 
was significantly shorter in patients with high, rather than low, expression of two 
HOX genes (HOXA10 and B3), and significantly longer in patients with high rather 
than low HOXC5 expression. Dysregulated expression of the HOXA10, B3, and C5 was 
significantly correlated with overall survival in EOC patients. HOX gene expression 
levels are potentially useful as a prognostic indicator in EOC, and HOX genes may 
represent a novel and promising target for anticancer therapeutics.
INTRODUCTION
Epithelial ovarian cancer (EOC), the leading cause 
of gynecologic cancer-related mortality, is known to be 
a multifactorial disease involving genetic, environmental, 
and epigenetic factors [1, 2]. Recently, research has 
focused on aberrant variation in the expression of 
transcription factors and its importance in the development 
of this malignancy [3].
Homeobox (HOX) genes, defined by a highly 
conserved 183-base pair DNA sequence called the 
homeobox, encode homeoproteins that function as 
transcription factors in differentiation and proliferation 
processes during embryonic structural development [4]. 
Aberrant expression of these proteins has been associated 
with carcinogenesis and aggressiveness [5, 6]. This is 
consistent with the idea that expression levels of many 
genes involved in normal embryogenesis are aberrant in 
various malignancies [7].
Previous studies showed that dysregulation of 
several HOX genes (including aberrant expression of 
HOXA7, HOXA9, HOXC8, HOXB13, and HOXC6) 
was associated with adverse prognostic factors in EOC; 
however, the majority of this research was limited by 
small sample sizes and was performed only in vitro 
[8–14]. Several studies have shown potential roles for 
HOX antisense long non-coding RNAs in ovarian cancer 
aggressiveness [15, 16]. These results suggest that aberrant 
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expression of HOX genes may be correlated with the 
process of ovarian cancer carcinogenesis.
We analyzed the mRNA expression level of all 
39 HOX genes using data from The Cancer Genome 
Atlas (TCGA) database on epithelial ovarian cancer and 
explored correlations with clinical data, including survival 
outcomes. We also evaluated the prognostic value of HOX 
gene expression analysis.
RESULTS
In total, we included 630 ovarian cancer cases, 
which were all the patients who included in the TCGA 
ovarian cancer database. The median follow-up 
period was 34.0 months (range, 0.3–182.7 months). 
Among clinicopathological features, age at the time 
of diagnosis, advanced Federation of Gynecology and 
Obstetrics (FIGO) stage, suboptimal residual disease, 
and poor Eastern Cooperative Oncology Group (ECOG) 
performance status were found to be independent 
predictive factors for overall survival in multivariate Cox 
regression analysis (Table 1).
Table 2 shows correlations between 
clinicopathological features and mRNA expression levels 
of HOX family genes. When the cases were categorized 
into low and high mRNA expression groups based on 
cut-off values determined as the median for each gene, 
higher expression of HOXA1 (P = 0.011), A4 (P = 0.045), 
A5 (P = 0.01), A7 (P = 0.047), A10 (P = 0.009), A11 (P = 
0.001), B13 (P = 0.01), C13 (P = 0.022), D1 (P = 0.004), 
and D3 (P = 0.011) was associated with advanced FIGO 
stage. Suboptimal residual disease after debulking surgery 
was significantly correlated with higher expression of 
HOXB9 (P = 0.002), B13 (P = 0.008), and C13 (P = 0.04). 
In addition, patients with high expression of HOXC6 (P = 
0.018) and C11 (P = 0.049) were significantly more likely 
to have poor performance status (ECOG 2 or 3).
Out of the total 630 patients, 584 patients (92.7%) 
had information on both prognostic value and microarray 
for the transcriptome analysis, so the prognosis of the 584 
patients was analyzed. Kaplan-Meier survival analysis 
showed that overall survival (OS) was significantly shorter 
in patients with high rather than low expression levels of 
HOXA10 (P = 0.008, median OS: 36 vs. 32 months) and 
HOXB3 (P = 0.003, median OS: 34 vs. 32 months), and 
significantly longer in patients with high rather than low 
HOXC5 expression (P = 0.022, median OS: 33 vs. 35 
months) (Figure 1). Multivariate Cox regression analysis 
of HOX gene expression also demonstrated that HOXA10 
and HOXB3 were significant positive predictive factors 
[odds ratio (OR): 1.305 and 1.462, 95% confidence 
interval (CI): 1.052–1.619 and 1.174–1.822, respectively], 
while HOXC5 (OR: 0.713, 95% CI: 0.572–0.889) was a 
significant negative predictive factor for overall survival 
(Figure 2).
DISCUSSION
In this study, we demonstrated that increased mRNA 
expression of certain HOX genes was independently 
associated with multiple risk factors, including advanced 
FIGO stage, suboptimal residual disease, and poor 
performance status, that were found to influence survival 
outcomes in ovarian cancer using the TCGA database. 
Specifically, upregulation of HOXA10 and HOXB3 
genes and downregulation of HOXC5 were significantly 
associated with unfavorable survival outcomes in patients 
with ovarian cancer.
Accumulating evidence indicates that HOX 
genes may be useful biomarkers to predict and evaluate 
responses to chemotherapy [17]. Our results were not 
completely consistent with those of previous in vitro 
research. In particular, the clinical relevance of HOXB3 
and HOXC5 was not known until now. This might be 
explained by the fact that the majority of studies reported 
to date have been retrospective in nature or conducted in 
small sized patient cohorts. To the best of our knowledge, 
this is the first study of HOX genes performed using 
clinical data from TCGA database. Also, it is feasible to 
clinically classify each subtype to determine the prognosis 
based on the results of this study. Further functional 
studies are required to identify the specific mechanisms 
by which HOX gene dysregulation influences oncogenesis.
During embryogenesis, as well as in adult 
tissues, growth, differentiation, and organization of cell 
populations are tightly coordinated and controlled [18]. 
In contrast, cancer has been identified as aberrations of 
these basic processes [19]. The oncogerminative theory of 
carcinogenesis suggests that malignant transformation is 
due to the aberrant expression of embryogenesis-related 
genes [20]. According to this concept, carcinogenesis is 
a dynamic self-organizing process that is similar to the 
process of early embryo development. Additionally, the 
malignant transformation that arises from gene mutations, 
in combination with epigenetic dysregulation, may 
reprogram somatic cells into immortal cells that simulate 
germline cells; this is consistent with cancer stem cells 
[20].
A substantial body of evidence supports a crucial 
role for HOX genes as developmental genes during 
embryogenesis, and also supports the critical role of 
aberrant HOX gene expression in the development of 
various tumors, specifically in ovarian cancer [5–7, 17, 
21, 22]. Further research is needed to elucidate all roles 
of HOX genes in ovarian cancer. A major limitation of this 
study is the short-term follow-up period, and the small 
number of overall mortalities during the period might 
weaken the clinical applicability of the current findings. 
A more comprehensive investigation is promising in the 
further analysis based on the regularly updated TCGA data 
in the future. Although this study proved the hypothesis 
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that dysregulated expression of HOX genes, based on 
microarray data, was correlated with altered survival 
outcomes in EOC, further validation using a different 
modality, such as large-volume RNA sequencing or 
immunohistochemical assay, might also be needed to 
verify the current results.
Analyzing HOX gene expression levels in a 
cytologic or surgical specimen can facilitate the selection 
of patients with ovarian cancer who are expected to have 
a poor prognosis. Based on analytical results, we can 
prescribe more aggressive treatment or more frequent 
follow-up for cases with an expected high risk. Moreover, 
Table 1: Correlation between clinicopathological features and overall mortality
Variables Total n = 630 n (%)
Multivariate analysis
HR (95% CI) P
Age    
 <45 54 (8.6) 1 (Reference) 0.042
 ≥45 553 (87.8) 1.512 (0.991-2.309)  
 N/A 23 (3.7)   
Stage    
 I 18 (2.9) 1 (Reference) 0.002
 II 33 (5.2)   
 III 462 (73.3) 2.264 (1.272-4.029)  
 IV 89 (14.1)   
 N/A 28 (4.4)   
Histology    
 Serous 607 (96.3)   
 N/A 23 (3.7)   
Grade    
 1, 2 85 (13.5) 1 (Reference) 0.253
 3, 4 505 (80.2) 1.189 (0.884-1.598)  
 N/A 40 (6.3)   
LN metastasis    
 No 85 (13.5) 1 (Reference) 0.125
 Yes 139 (22.1) 1.387 (0.913-2.107)  
 N/A 406 (64.4)   
Residual disease    
 ≤ 1 cm 387 (61.4) 1 (Reference) <0.001
 ≤ 2 cm 151 (24.0) 1.548 (1.222-1.960)  
 N/A 92 (14.6)   
ECOG    
 0, 1 123 (19.5) 1 (Reference) 0.002
 2, 3 12 (1.9) 3.317 (1.552-7.087)  
 N/A 495 (78.6)   
N/A, not available; ECOG, The Eastern Cooperative Oncology Group performance status; HR, hazard ratio; CI, confidence 
interval; LN, lymph node.
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Table 2: Summary of the correlation between clinicopathological features and mRNA expression counts of homeobox 
(HOX) family genes
Age≥45 Stage III/IV Grade 3/4 LN metastasis Residual disease > 1 cm ECOG 2, 3
HOXA1  +     
HOXA2       
HOXA3    +   
HOXA4  +     
HOXA5  +  +   
HOXA6       
HOXA7  +     
HOXA9       
HOXA10  ++     
HOXA11  ++  +   
HOXA13       
HOXB1       
HOXB2    ++   
HOXB3   +    
HOXB4       
HOXB5       
HOXB6       
HOXB7       
HOXB8       
HOXB9     ++  
HOXB13  +   ++  
HOXC4       
HOXC5       
HOXC6      +
HOXC8       
HOXC9       
HOXC10       
HOXC11      +
HOXC12       
HOXC13  +   +  
HOXD1  ++     
HOXD3  + ++    
HOXD4       
HOXD8       
HOXD9       
HOXD10       
HOXD11    ++   
HOXD12    ++   
HOXD13   +    
+, Correlation with P value < 0.05; ++, correlation with P value <0.01; LN, lymph node; ECOG, The Eastern Cooperative 
Oncology Group performance status.
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Figure 1: Kaplan-Meier survival analysis of 584 patients with ovarian cancer stratified by (A) HOXA10, (B) HOXB3, and (C) HOXC5 
gene expression levels on microarray.
Figure 2: Multivariate analyses of homeobox (HOX) gene expression predicting overall survival. CI, confidence interval.
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there are great unmet needs of patients with refractory 
ovarian cancer that recurs after treatment with standard 
therapy, which demands novel therapeutic agents. Drugs 
regulating HOX gene expression could potentially 
have a therapeutic effect by inducing inhibition of 
reprogramed oncogerminative cells, as was shown by in 
vitro experiments using a homeobox transcription factor 
inhibitor [23]. Recently, decitabine, a drug that induced 
CpG island hypomethylation of HOXA10 and HOXA11 
genes, showed significant correlation with improved 
progression-free survival in an open-label, single-center, 
phase II clinical trial [24].
In conclusion, dysregulated expression of the 
HOXA10, HOXB3, and HOXC5 genes was significantly 
associated with favorable or unfavorable overall survival 
in a large ovarian cancer cohort from TCGA. Additionally, 
many of the HOX genes were correlated with clinical 
variables that were independent predictive factors for 
overall survival. Evaluation of HOX gene expression may 
be potentially valuable as a marker to predict prognosis in 
serous ovarian cancer.
MATERIALS AND METHODS
Data acquisition
We collected mRNA expression data for 39 HOX 
family genes and corresponding clinicopathological 
information from the TCGA data portal (https://tcga-data.
nci.nih.gov/tcga/tcgaDownload.jsp). The patient personal 
information is anonymized and deidentified. According to 
the TCGA publication guidelines (http://cancergenome.
nih.gov/publications/publicationguidelines), these mRNA 
sequencing data have no restrictions on publication, 
and no additional approval by an ethics committee 
was required to publish findings utilizing the data. The 
database compiled from microarray analysis performed 
using GeneChip Human Genome U133A 2.0 Array 
(Affymetrix) was analyzed in this study.
Patient information
We obtained the mRNA expression levels of 39 
HOX family genes for each patient, along with their 
clinicopathologic features, including age at initial 
pathologic diagnosis, International FIGO stage, histologic 
subtype, lymph node metastasis, and overall survival 
(Supplementary Table 1).
Statistical analyses
We used the Fisher exact or χ2 tests for categorical 
variables, according to sample size. Linear regression was 
applied to assess associations between clinical variables 
and each HOX gene expression count. Medians of HOX 
gene expression were determined as the cut-off value for 
prediction of survival. Kaplan-Meier survival analyses 
and multivariate Cox regression analysis based on the 
calculated cut-off values were performed. SPSS version 
23.0 (IBM Corp., Armonk, NY, USA) was used for data 
analysis.
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